Insider · CIK 0001864486
Salim Yazji
Files at ONCT (Oncternal Therapeutics, Inc.). First filing Apr 14, 2023, latest Apr 14, 2023.
In brief
Salim Yazji files SEC Form 4 as officer at ONCT (Oncternal Therapeutics, Inc.). Since Apr 14, 2023, Salim Yazji has reported 1 open-market buy worth $7,200 and 0 open-market sells worth $0, the latest filed on Apr 14, 2023.
A track record needs three past buys with six months of prices behind them; Salim Yazji has 0, so none is measured yet.
The newest scored trade: bought $7,200 of ONCT on Apr 12, 2023, filed Apr 14, 2023, scored 33 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Oncternal Therapeutics, Inc. | $7,200 25,000 shares | +18% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 15, 2024 | Oncternal Therapeutics, Inc. | 4,681 0.16% of outstanding | $5,009 | Oct 14, 2024 | $1,960 |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 14, 2024 | ONCT Oncternal Therapeutics, Inc. | AGrant or award Stock Optionderivative | +14,200 | $0.00 | $0 | 14,200 | Feb 15, 2024 |
| Jan 3, 2024 | ONCT Oncternal Therapeutics, Inc. | FTax withholding Common Stock | -19,742 | $0.50 | $9,794 | 128,635 | Jan 5, 2024 |
| Apr 12, 2023 | ONCT Oncternal Therapeutics, Inc. | POpen-market purchase Common Stock | +10,000 | $0.29 | $2,850 | 149,676 | Apr 14, 2023 |
| Apr 13, 2023 | ONCT Oncternal Therapeutics, Inc. | POpen-market purchase Common Stock | +10,000 | $0.29 | $2,850 | 159,676 | Apr 14, 2023 |
| Apr 14, 2023 | ONCT Oncternal Therapeutics, Inc. | POpen-market purchase Common Stock | +5,000 | $0.30 | $1,500 | 164,676 | Apr 14, 2023 |
| Feb 21, 2023 | ONCT Oncternal Therapeutics, Inc. | AGrant or award Stock Optionderivative | +210,000 | $0.00 | $0 | 210,000 | Feb 23, 2023 |
| Jan 3, 2023 | ONCT Oncternal Therapeutics, Inc. | FTax withholding Common Stock | -9,961 | $1.02 | $10k | 139,676 | Jan 5, 2023 |
Questions about Salim Yazji
Answered from the filings on this page, as of the latest one.
Is Salim Yazji buying or selling?
Not in the last 12 months. Salim Yazji's latest open-market trade on SEC Form 4 was bought $7,200 of ONCT on Apr 12, 2023.
How did Salim Yazji's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Salim Yazji has 0.
Where does Salim Yazji file Form 4?
Salim Yazji has filed Form 4 at ONCT (Oncternal Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.